China Approves SGC001 IND Application for Severe Acute Pancreatitis, Expanding Multi-Indication Pipeline

GateNews
According to a May 25 announcement from Rejing Biotech, its subsidiary Shunjing Pharma received approval from China's National Medical Products Administration for a clinical trial application of SGC001 injection for severe acute pancreatitis. The investigational drug, which carries potential First-in-Class value, is advancing into multi-indication development following ongoing Phase II trials for acute myocardial infarction.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments